No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
On November 28, He Bo Pharmaceutical-B (02142.HK) spent 0.071 million HKD to repurchase 0.06 million shares.
Glory Capital announced on November 28 that Heber Medical-B (02142.HK) repurchased 0.06 million shares on November 28, 2024, at a cost of 0.071 million Hong Kong dollars, with a repurchase price of 1.18-1.19 Hong Kong dollars per share.
Heptagon Pharmaceuticals-B (02142.HK) spent HKD 0.2404 million to repurchase 0.2 million shares on November 25.
Gelonghui, November 25th丨Hepalink Pharmaceutical-B (02142.HK) announced that on November 25, 2024, it spent 0.2404 million HKD to repurchase 0.2 million shares, with a repurchase price of 1.19-1.21 HKD per share.
On November 22, Huabo Pharmaceuticals-B (02142.HK) spent 0.244 million Hong Kong dollars to repurchase 0.2 million shares.
On November 22, Gelonghui announced that Heber Pharmaceuticals-B (02142.HK) spent 0.244 million Hong Kong dollars to repurchase 0.2 million shares.
Express News | Harbour Biomed Appoints DR. Raymond Zheng as Chief Business Officer
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
